Sentences with phrase «years of oncology»

Applicants, preferably, would have one year of oncology experience and be confident with basic skills: venipuncture, IVC placement, drug calculation and administration, anesthesia monitoring, patient restraint and record keeping.

Not exact matches

These products — largely innovative and pricey specialty medications that include breakthrough Hepatitis C treatments and immuno - oncology drugs — reflect the increased productivity and improved pipelines of pharma's R&D departments in recent years.

Even though getting a drug to market typically takes ten years, Linear, in its eight years of operation, has already been involved in assisting two oncology drugs to be available for cancer patients.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The adjusted tally beat consensus expectations of $ 1.00, thanks in part to stronger demand for its standout immuno - oncology drug KEYTRUDA, and management responded by raising its full - year guidance.

They say they expect next year to start up to 20 patient testing programs of such immuno - oncology drugs.

With major clinical successes in areas such as CAR - T, gene therapy, immune - oncology, cell therapy and gene editing, many see 2017 as the year that biotech really came of age.

Immunotherapy has been emerging from the backdrop of oncology research for years most notably from smaller companies such as Dendreon, Kite Pharma and Juno Therapeutics as leaders in the space.

This biotech's first year as a publicly traded company has been a terrific ride on the back of an experimental oncology therapy that could have huge built - in demand.

Combine this with dozens of oncology and ant - inflammatory collaborations for potentially first - in - class therapies, and you have a recipe for double - digit annual sales growth for years to come.

His interest in research grew while he did his medical degree at Stanford, so he enrolled in Stanford's research - residency program, which allowed him to do 2 years of traditional residency training with a 3rd - year research fellowship in hematology - oncology.

Also published today in Gynecologic Oncology is the end - of - trial data of the Roche Diagnostics ATHENA HPV trial that enrolled more than 47,000 women in a longitudinal, three - year study of Roche's HPV test.

Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab group had nearly double the survival rate (42 percent) of the chemotherapy patients (24 percent).

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

NRG Oncology / RTOG 0232 is a phase III, multi-institutional trial conducted at 68 cancer centers throughout the U.S. and Canada from 2003 to 2012 to assess whether adding EBT to transperineal interstitial permanent brachytherapy conveyed an additional benefit in progression free survival (PFS), or control of the cancer growth, at five years following treatment.

A paper he published early this year in the Journal of Clinical Oncology describes a dendritic cell vaccine in advanced glioma, an aggressive form of brain cancer.

People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research meeting.

«This is not positive news for astronauts deployed on a two - to - three - year round trip to Mars,» said the professor of radiation oncology in UCI's School of Medicine.

And over the last eight or nine years we've looked at the general world of unmet needs such as an oncology franchise, autoimmune disorders, and other diseases.»

She worked with Ganz for 3 years as a junior scientist, learning about cancer and chronic disease and charting a course in the relatively new field of psycho - oncology before applying for her own research funding.

Fast forward 2 years: Gray is working as a postdoc in the lab of USC oncology researcher Michael Wong, on a nanoparticle drug delivery system.

Published in the journal Tobacco Control, the first study to model public health outcomes if cigarette smoking was replaced by e-cigarettes «supports a policy strategy that encourages replacing cigarette smoking with vaping to yield substantial life year gains,» says the study's lead author David Levy, PhD, professor of oncology at Georgetown Lombardi.

«It's 11 questions, and it's not hard to do,» says Hurria, who just completed a two - year term as president of the International Society of Geriatric Oncology.

However, what our trial has shown is that although this is still the case, the proportion of women who will actually have a recurrence without radiotherapy is very small (less than 5 percent), five years after treatment,» said Ian Kunkler, F.R.C.R., professor of clinical oncology at the Edinburgh Cancer Research Center in the University of Edinburgh.

«The team recently published their results in the Journal of Thoracic Oncology and found that the procedure was well tolerated at all ages — even in those patients aged over 80 years old.

«This is something that's been on our minds for years, really since the early 2000s, and it's exciting to see it finally come to fruition,» said James Metz, MD, chair of Radiation Oncology at Penn Medicine.

David Blask, a colleague of Hill's at Tulane who runs the Laboratory of Chrono - Neuroendocrine Oncology there, has been studying the effects of melatonin on cancer for almost 40 years.

Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow - up show that 5 - FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)- radiotherapy for patients with cT3 - resectable T4 M0 rectal cancer does not improve survival or disease - free survival.

«Over the past several years, with advances in technology, radiation to only the surgical bed of the resected lesion has become of interest,» said Anita Mahajan, MD, professor of radiation oncology at MD Anderson Cancer Center in Houston and lead author of the study.

The designation recognises that centres have achieved a high standard of integration of medical oncology and palliative care and is valid for three years.

Three years after IBM began selling Watson for Oncology to recommend cancer treatments to doctors, it's falling short of the lofty expectations IBM created for it

«This study, one of only a few large studies to have follow - up beyond five years, demonstrates that patients who have head and neck cancers and who are being treated with radiation therapy alone have improved local - regional control and no increase in late toxicity when radiation therapy is delivered twice a day in two smaller doses which we call hyperfractionation,» said Jonathan J. Beitler, MD, MBA, FASTRO, lead author of the study and professor of radiation oncology, otolaryngology and hematology / medical oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta.

Previously described as the «guardian of the genome» and voted «Molecule of the Year» in 1993, p53 is one of the most important proteins regulating cell growth and a major focus for oncology research.

Now in the second year of her PhD in Silvio Parodi's experimental oncology group at the National Institute for Cancer Research in Genoa, Stefania Pasa (see photo) was a studious child who often «preferred to... study rather than go out to the cinema.»

Published by Noha Sharafeldin, M.D., M.Sc., Ph.D., instructor in UAB's Institute for Cancer Outcomes and Survivorship and Division of Hematology and Oncology, this study helps add a missing piece to a long - unsolved puzzle about post-transplant effects on recipients, specifically that vulnerable subpopulations of similar transplants can benefit from targeted interventions in the years after they receive their lifesaving treatment.

«That said, there are groups of patients with metastatic disease who can live much longer,» says James Yao, associate professor and deputy chairman in gastrointestinal medical oncology at the University of Texas M. D. Anderson Cancer Center, «some even up to 5 to 10 years.»

Use of oral contraceptives (usually referred to as «the pill»), even for just a few years, gives substantial long - term protection against endometrial (womb) cancer, and the longer the pill is used the greater the reduction in risk, according to a detailed re-analysis of all the available evidence, published in The Lancet Oncology journal.

Men with newly diagnosed metastatic, hormone - sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone - blockers, report scientists from Dana - Farber Cancer Institute and the Eastern Co-operative Oncology Group.

Andrae Vandross is currently a Hematology and Medical Oncology fellow in his final year of training at UCLA.

«We've known for years that how well a patient does is directly related to the amount of tumor that the surgeon removes and the amount that's left behind,» says Michael Birrer, who began working with Belcher when he was head of medical gynecologic oncology at Massachusetts General Hospital.

During the years, a number of renovations have been made and services added including Radiation Oncology, Computer - Assisted Minimally - Invasive Orthopaedic Surgery, Digital Mammography, Fixed Cardiac Catheterization, MRI, Inpatient Dialysis, 24 - hour Emergency Services, Cardio - pulmonary; Laboratory; Diagnostic Imaging and Physical Therapy.

He was clinical professor of medicine and practiced hematology and oncology for 24 years at the Long Beach Community Hospital.

Asha Pillai, M.D., a specialist in pediatric hematology - oncology, was named «Cancer Researcher of the Year» by the Woman's Cancer Association of the University of Miami at its «Dancing for a Cure» Gala.

Commenting on the significance of the research, Dr Pilar Garrido, head of the Thoracic Tumour Section of the Medical Oncology Department at Ramón y Cajal University Hospital, Madrid, Spain, said: «Lung cancer is the most common cancer globally, but debate about the optimal screening strategy is ongoing and current selection criteria are based only on age and pack - years.

The authors built a statistical simulation model to estimate the 25 - year incremental costs per quality - adjusted life - year (QALY) for Oncotype DX testing in order to evaluate the cost - effectiveness of GEP testing among patients with early - stage ER - positive / HER2 - negative breast cancer treated in community oncology practices.

At the University of Chicago Center for Gastrointestinal Oncology, our cancer specialists have many years of experience treating stomach cancer (also known as gastric cancer).

Based on our findings, the occurrence of cancer is much higher in adults over 75 years of age compared with the proportion of patients in this age group who enroll in clinical trials,» said lead study author Bindu Kanapuru, MD, medical officer in the Division of Hematology Products, Office of Hematology and Oncology Products in the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, who presented the results at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9 — 12 in Atlanta.

The Commission on Cancer of the American College of Surgeons validated the excellence of DeKalb Medical's cancer care program by granting them a three - year approval as a community hospital comprehensive oncology program.

Board - certified in internal medicine and medical oncology, Dr. Collins has 25 years of experience in bone marrow transplantation and has participated in some 2,500 autologous and allogeneic transplants.

Prior to that, Graziano spent five years working in academic research at New York University's School of Medicine, studying oncology and cardiovascular diseases.